0000896747 abmc:RICOHMember 2007-05-31 0000896747 abmc:RICOHMember 2007-05-01 2007-05-31 0000896747 abmc:SeriesADebenturesMember 2008-08-01 0000896747 abmc:CantoneSeriesOneFourYearWarrantsMember 2008-08-01 0000896747 2009-06-29 0000896747 abmc:MedallionFinancingStockOptionMember abmc:JaskiewiczMember 2009-07-01 0000896747 abmc:TwoThousandAndOnePlanMember abmc:RosenthalFinancingStockOptionMember abmc:CipkowskiMember 2009-07-01 0000896747 abmc:MedallionFinancingStockOptionMember abmc:JaskiewiczMember 2009-07-02 2009-07-31 0000896747 abmc:MedallionFinancingStockOptionMember abmc:JaskiewiczMember 2009-01-01 2009-12-31 0000896747 abmc:MedallionFinancingStockOptionMember abmc:JaskiewiczMember 2010-07-01 0000896747 abmc:MedallionFinancingStockOptionMember abmc:JaskiewiczMember 2010-07-02 2010-07-31 0000896747 abmc:TwoThousandAndOnePlanMember 2010-07-02 2010-07-31 0000896747 abmc:MarlinLeasingMember 2010-10-31 0000896747 abmc:TwoThousandAndOnePlanMember abmc:EmployeeOptionGrantMember 2010-10-31 0000896747 abmc:MarlinLeasingMember 2010-10-01 2010-10-31 0000896747 2010-12-31 0000896747 abmc:TwoThousandAndOnePlanMember abmc:EmployeeOptionGrantMember 2010-12-31 0000896747 2010-12-01 2010-12-31 0000896747 abmc:EachCauseOfActionsMember 2010-12-01 2010-12-31 0000896747 abmc:FirstNiagaraBankMortgageConsolidationLoanMember 2011-02-23 0000896747 2011-03-01 2011-03-31 0000896747 us-gaap:PendingLitigationMember 2011-03-01 2011-03-31 0000896747 abmc:MedallionFinancingStockOptionMember abmc:JaskiewiczMember 2011-07-01 0000896747 abmc:MedallionFinancingStockOptionMember abmc:JaskiewiczMember 2011-07-02 2011-07-31 0000896747 abmc:TwoThousandAndOnePlanMember 2011-07-02 2011-07-31 0000896747 2011-07-02 2011-09-30 0000896747 abmc:SeriesADebenturesMember 2011-07-02 2011-09-30 0000896747 abmc:CantoneSeriesOneFourYearWarrantsMember 2011-07-02 2011-09-30 0000896747 abmc:MedallionFinancingStockOptionMember abmc:JaskiewiczMember 2011-07-02 2011-09-30 0000896747 abmc:TwoThousandAndOnePlanMember 2011-07-02 2011-09-30 0000896747 abmc:FirstNiagaraBankMortgageConsolidationLoanMember 2011-07-02 2011-09-30 0000896747 abmc:RosenthalMember 2011-07-02 2011-09-30 0000896747 2011-01-01 2011-09-30 0000896747 abmc:SeriesADebenturesMember 2011-01-01 2011-09-30 0000896747 abmc:CantoneSeriesOneFourYearWarrantsMember 2011-01-01 2011-09-30 0000896747 abmc:TwoThousandAndOnePlanMember 2011-01-01 2011-09-30 0000896747 abmc:FirstNiagaraBankMortgageConsolidationLoanMember 2011-01-01 2011-09-30 0000896747 abmc:RosenthalMember 2011-01-01 2011-09-30 0000896747 2011-09-30 0000896747 abmc:RosenthalMember 2011-09-30 0000896747 abmc:TwoThousandAndOnePlanMember 2011-04-01 2011-12-31 0000896747 abmc:SeriesADebenturesMember 2011-01-01 2011-12-31 0000896747 abmc:TwoThousandAndOnePlanMember 2011-01-01 2011-12-31 0000896747 2011-12-31 0000896747 abmc:RICOHMember 2011-12-31 0000896747 abmc:SeriesADebenturesMember 2011-12-31 0000896747 abmc:CantoneSeriesOneFourYearWarrantsMember 2011-12-31 0000896747 abmc:MarlinLeasingMember 2011-12-31 0000896747 abmc:FirstNiagaraBankMortgageConsolidationLoanMember 2011-12-31 0000896747 abmc:RosenthalMember 2011-12-31 0000896747 abmc:TwoThousandAndOnePlanMember 2012-03-31 0000896747 abmc:MedallionMember 2012-04-20 0000896747 abmc:MedallionFinancingStockOptionMember abmc:JaskiewiczMember 2012-04-01 2012-04-20 0000896747 abmc:RosenthalMember 2012-04-01 2012-04-20 0000896747 abmc:MedallionFinancingStockOptionMember abmc:UrquhartMember 2012-04-01 2012-04-20 0000896747 abmc:TwoThousandAndOnePlanMember 2012-07-03 2012-07-31 0000896747 2012-07-01 2012-09-30 0000896747 abmc:SeriesADebenturesMember 2012-07-01 2012-09-30 0000896747 abmc:CantoneSeriesOneFourYearWarrantsMember 2012-07-01 2012-09-30 0000896747 abmc:TwoThousandAndOnePlanMember 2012-07-01 2012-09-30 0000896747 abmc:FirstNiagaraBankMortgageConsolidationLoanMember 2012-07-01 2012-09-30 0000896747 abmc:RosenthalMember 2012-07-01 2012-09-30 0000896747 abmc:MedallionMember 2012-07-01 2012-09-30 0000896747 abmc:CamWarrantsMember 2012-07-01 2012-09-30 0000896747 abmc:CriWarrantsMember 2012-07-01 2012-09-30 0000896747 abmc:September2012EmployeeGrantsMember 2012-07-01 2012-09-30 0000896747 abmc:UrquhartMedallionGrantMember 2012-07-01 2012-09-30 0000896747 abmc:JaskiewiczMedallionGrantMember 2012-07-01 2012-09-30 0000896747 abmc:April202013Member abmc:CipkowskiMedallionGrantMember 2012-07-01 2012-09-30 0000896747 abmc:April202014Member abmc:CipkowskiMedallionGrantMember 2012-07-01 2012-09-30 0000896747 abmc:April202015Member abmc:CipkowskiMedallionGrantMember 2012-07-01 2012-09-30 0000896747 abmc:CipkowskiMedallionGrantMember 2012-07-01 2012-09-30 0000896747 abmc:April202013Member abmc:UrquhartMedallionGrantMember 2012-07-01 2012-09-30 0000896747 abmc:April202014Member abmc:UrquhartMedallionGrantMember 2012-07-01 2012-09-30 0000896747 abmc:April202015Member abmc:UrquhartMedallionGrantMember 2012-07-01 2012-09-30 0000896747 abmc:April202013Member abmc:JaskiewiczMedallionGrantMember 2012-07-01 2012-09-30 0000896747 abmc:April202014Member abmc:JaskiewiczMedallionGrantMember 2012-07-01 2012-09-30 0000896747 abmc:April202015Member abmc:JaskiewiczMedallionGrantMember 2012-07-01 2012-09-30 0000896747 2012-01-01 2012-09-30 0000896747 abmc:RICOHMember 2012-01-01 2012-09-30 0000896747 abmc:SeriesADebenturesMember 2012-01-01 2012-09-30 0000896747 abmc:CantoneSeriesOneFourYearWarrantsMember 2012-01-01 2012-09-30 0000896747 abmc:TwoThousandAndOnePlanMember 2012-01-01 2012-09-30 0000896747 abmc:FirstNiagaraBankMortgageConsolidationLoanMember 2012-01-01 2012-09-30 0000896747 abmc:RosenthalMember 2012-01-01 2012-09-30 0000896747 abmc:MedallionMember 2012-01-01 2012-09-30 0000896747 abmc:CamWarrantsMember 2012-01-01 2012-09-30 0000896747 abmc:CriWarrantsMember 2012-01-01 2012-09-30 0000896747 abmc:September2012EmployeeGrantsMember 2012-01-01 2012-09-30 0000896747 abmc:UrquhartMedallionGrantMember 2012-01-01 2012-09-30 0000896747 abmc:JaskiewiczMedallionGrantMember 2012-01-01 2012-09-30 0000896747 abmc:CipkowskiMedallionGrantMember 2012-01-01 2012-09-30 0000896747 abmc:TwoThousandAndOnePlanMember abmc:MedallionFinancingStockOptionMember 2012-01-01 2012-09-30 0000896747 abmc:WallStreetJournalPrimeMember 2012-01-01 2012-09-30 0000896747 abmc:September2012EmployeeGrantsMember abmc:September202013Member 2012-01-01 2012-09-30 0000896747 abmc:September2012EmployeeGrantsMember abmc:September202014Member 2012-01-01 2012-09-30 0000896747 abmc:September2012EmployeeGrantsMember abmc:September202015Member 2012-01-01 2012-09-30 0000896747 abmc:September2012EmployeeGrantsMember abmc:TwoNonExecutiveEmployeesMember 2012-01-01 2012-09-30 0000896747 abmc:FiveDebenturesHoldersMember 2012-01-01 2012-09-30 0000896747 us-gaap:BridgeLoanMember 2012-01-01 2012-09-30 0000896747 abmc:EmployeeOptionGrantMember 2012-01-01 2012-09-30 0000896747 2012-09-30 0000896747 abmc:RICOHMember 2012-09-30 0000896747 abmc:SeriesADebenturesMember 2012-09-30 0000896747 abmc:CantoneSeriesOneFourYearWarrantsMember 2012-09-30 0000896747 abmc:MarlinLeasingMember 2012-09-30 0000896747 abmc:FirstNiagaraBankMortgageConsolidationLoanMember 2012-09-30 0000896747 abmc:RosenthalMember 2012-09-30 0000896747 abmc:MedallionMember 2012-09-30 0000896747 abmc:CamWarrantsMember 2012-09-30 0000896747 abmc:CriWarrantsMember 2012-09-30 0000896747 abmc:September2012EmployeeGrantsMember 2012-09-30 0000896747 abmc:UrquhartMedallionGrantMember 2012-09-30 0000896747 abmc:JaskiewiczMedallionGrantMember 2012-09-30 0000896747 abmc:CipkowskiMedallionGrantMember 2012-09-30 0000896747 abmc:TwoThousandAndOnePlanMember abmc:MedallionFinancingStockOptionMember 2012-09-30 0000896747 abmc:EmployeeOptionGrantMember 2012-09-30 0000896747 2012-11-30 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure AMERICAN BIO MEDICA CORP 0000896747 --12-31 Smaller Reporting Company abmc 21833003 10-Q false 2012-09-30 Q3 2012 37000 22000 93000 0 883000 1242000 3239000 3079000 61000 83000 4276000 4404000 1304000 1225000 26000 19000 42000 0 0 23000 30000 26000 5636000 5720000 631000 1027000 217000 195000 264000 290000 397000 565000 872000 1435000 10000 10000 2391000 3536000 143000 144000 608000 0 124000 124000 124000 3266000 3804000 0 0 217000 217000 19386000 19479000 -17233000 -17780000 2370000 1916000 5636000 5720000 66000 50000 401000 469000 0.01 0.01 5000000 5000000 0 0 0 0 0.01 0.01 50000000 50000000 21744768 21833003 21744768 21833003 2365000 6898000 2283000 7041000 1399000 4019000 1392000 4145000 966000 2879000 891000 2896000 61000 170000 54000 162000 417000 1319000 453000 1503000 462000 1563000 613000 1658000 940000 3052000 1120000 3323000 26000 -173000 -229000 -427000 -1000 0 0 0 3000 8000 49000 150000 38000 129000 -49000 -151000 -35000 -121000 -23000 -324000 -264000 -548000 5000 6000 0 -2000 -28000 -330000 -264000 -546000 -0.00 -0.02 -0.01 -0.03 21744768 21744768 21833003 21833003 208000 91000 8000 35000 24000 3000 34000 19000 14000 16000 6000 -68000 8000 3000 6000 6000 45000 20000 0 8000 3000 1000 4000 2000 4000 93000 13000 8000 3000 1000 8000 4000 8000 381000 344000 -434000 -92000 28000 21000 3000 252000 394000 -63000 -1000 36000 26000 2000 2000 191000 -125000 141000 12000 0 -23000 -141000 -35000 103000 201000 0 -50000 0 150000 11000 0 27000 168000 -65000 67000 -15000 -93000 170000 152000 <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Note A - Basis of Reporting</b></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The accompanying unaudited interim financial statements of American Bio Medica Corporation (the &#8220;Company&#8221;) have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and in accordance with the instructions to Form 10-Q and Regulation S-X. Accordingly, these unaudited interim financial statements do not include all information and footnotes required by U.S. GAAP for complete financial statement presentation. These unaudited interim financial statements should be read in conjunction with our audited financial statements and related notes contained in our Annual Report on Form 10-K for the year ended December 31, 2011. In the opinion of management, the interim financial statements include all normal, recurring adjustments which are considered necessary for a fair presentation of the financial position of the Company at September 30, 2012, the results of our operations for the three and nine month periods ended September 30, 2012 and September 30, 2011, and cash flows for the nine month periods ended September 30, 2012 and September 30, 2011.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Operating results for the three and nine months ended September 30, 2012 are not necessarily indicative of results that may be expected for the year ending December 31, 2012. Amounts at December 31, 2011 are derived from our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2011.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">During the nine months ended September 30, 2012, there were no significant changes to our critical accounting policies, which are included in our Annual Report on Form 10-K for the year ended December 31, 2011.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The preparation of these interim financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate estimates, including those related to product returns, bad debts, inventories, income taxes, warranty obligations, contingencies and litigation. We base estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">These unaudited interim financial statements have been prepared assuming that the Company will continue as a going concern and, accordingly, do not include any adjustments that might result from the outcome of this uncertainty. Our independent registered public accounting firm&#8217;s report on the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2011, contained an explanatory paragraph regarding our ability to continue as a going concern. As of the date of this report, our current cash balances, together with cash generated from future operations and amounts available under current credit facilities may not be sufficient to fund operations for the next 12 months if sales levels do not improve (and an inability to market and sell our point of collection oral fluid drug tests in the Workplace market would negatively impact our revenues). If cash generated from operations is not sufficient to satisfy our working capital and capital expenditure requirements, we will be required to sell additional equity or obtain additional credit facilities. There is no assurance that such financing will be available or that we will be able to complete financing on satisfactory terms, if at all.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Recent Accounting Standards </b></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">There were no new standards adopted that are expected to have a material impact on our interim financial statements.</p> <p style="text-align: justify; margin: 0pt 0px; font: bold 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; margin: 0pt 0px; font: bold 10pt times new roman, times, serif;">Note B &#8211; Net Loss Per Common Share</p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Basic net loss per common share is calculated by dividing the net loss by the weighted average number of outstanding common shares during the period. Diluted net loss per common share includes the weighted average dilutive effect of stock options and warrants. Potential common shares outstanding as of September 30, 2012 and 2011:</p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p> <table align="center" style="width: 70%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">September 30, 2012</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">September 30, 2011</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="width: 32%; font-weight: bold;">Warrants</td> <td style="width: 1%; font-weight: bold;">&#160;</td> <td style="width: 1%;">&#160;</td> <td style="width: 1%;">&#160;</td> <td style="text-align: right; width: 31%;">375,000</td> <td style="width: 1%;">&#160;</td> <td style="width: 1%;">&#160;</td> <td style="width: 1%;">&#160;</td> <td style="text-align: right; width: 30%;">75,000</td> <td style="width: 1%;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="font-weight: bold;">Options</td> <td style="font-weight: bold;">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;">3,139,080</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;">3,081,580</td> <td>&#160;</td> </tr> </table> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">There were no securities included in the diluted net loss per common share for the three and nine months ended September 30, 2012 and September 30, 2011 (because the effect would have been anti-dilutive).</p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Note C &#8211; Litigation </b></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On December 16, 2010, we filed a complaint in the Supreme Court of the State of New York in Columbia County against Martin R. Gould (&#8220;Gould&#8221;), Jacqueline Gale (&#8220;Gale&#8221;), Advanced Diagnosticum Products, Inc. (&#8220;ADPI&#8221;) and Biosure, Inc. (&#8220;Biosure&#8221;), together the &#8220;Defendants&#8221;. The complaint alleges that Gould, our former Chief Science Officer and Executive Vice President of Technology, and Gale, our former Vice President of Manufacturing and Development, were performing illegal, competitive, employment-related services for ADPI and Biosure during their employment with the Company, were using Company resources to perform such services, and were doing so in their capacity as employees and/or officers of ADPI and Biosure. Because the Defendants continue to engage in illegal activity, in addition to the compensatory and punitive damages noted below, the complaint also seeks an injunction restraining the Defendants from engaging in further wrongdoing. The Defendants exercised their right to move the action to federal court, and proceedings are now pending in the United States District Court for the District of New Jersey.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In the Complaint, we assert claims of breach of duty of loyalty, breach of contract, violation of fiduciary duty and unfair competition and conversion specifically against Gould, and claims of breach of duty, violation of fiduciary duty and unfair competition and conversion specifically against Gale. In addition to these claims, we assert claims of conversion, tortious interference with contract, interference with prospective advantage and common law misappropriation of trade secret information against all Defendants. We are seeking judgment on nine (9) causes of action for compensatory damages against Defendants in such amount as may be established at trial, together with punitive damages in the amount of one million dollars ($1,000,000) for each cause of action in the Complaint (totaling $9,000,000).</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On March 28, 2011, the Defendants filed an Answer to our Complaint and Defendant Gould filed a counter-claim against the Company in the amount of $150,000 alleging breach of contract related to an employment agreement between Gould and the Company. We filed a reply to Gould&#8217;s counterclaim on April 13, 2011. Our reply asserted that the Company did not breach the prior employment agreement in place with Gould, that the Company provided the required written notice of non-renewal of Gould&#8217;s employment agreement, and that Gould&#8217;s employment agreement expired on May 31, 2010; at which time Gould became an at-will employee of the Company. Gould was subsequently terminated for cause on July 28, 2010. A conference was held with the court on June 16, 2011, at which issues in dispute were discussed and a discovery schedule was set. The Company has responded to the Defendants discovery requests and as of the date of this report, the Company is awaiting complete responsive discovery items from Defendants. Depositions in the matter are ongoing. Depositions and discovery were expected to be completed by April 30, 2012, however, pretrial discovery was extended to September 28, 2012 due to an unexpected personal issue that occurred involving the Defendants attorney; this unexpected issue was unrelated to the case or the claims of the case. On September 11, 2012, pretrial discovery was extended again to December 14, 2012.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As previously disclosed, we received a warning letter from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in July 2009 that alleges we re marketing our point of collection oral fluid drug test, OralStat, in workplace settings without marketing clearance or approval. A warning letter is considered by FDA to be informal and advisory. While a warning letter communicates FDA&#8217;s position on a matter it does not commit the FDA to taking enforcement action. We communicated to the FDA our belief (based on legal opinion) that marketing clearance was not required in non-clinical markets. The FDA continued to disagree with our interpretation of FDA regulations related to medical devices, and the FDA continued to assert jurisdiction of drug testing performed in the workplace. We also advised FDA that we were willing to obtain marketing clearance but that specific technical and scientific issues existed when attempting to utilize FDA&#8217;s draft guidance for our OralStat (because the draft guidance was written for urine drug tests). Nevertheless, we were unable to reach a consensus with the FDA on neither the jurisdiction issue nor the technical issues.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On July 10, 2012, we announced in a press release and a Current Report on Form 8-K that we entered into a Consent Decree of Permanent Injunction (the &#8220;Consent Decree&#8221;) with FDA. Under the terms of the Consent Decree, we will be allowed to continue to market our OralStat drug test in the workplace market while we take action to obtain a 510(k) marketing clearance. More specifically, FDA will provide the Company with its most recent guidance on the clinical and analytical studies that need to be conducted to gather data in support of a 510(k) submission for OralStat. We will then have a total of 396 days to discuss protocols with FDA, complete our analytical and clinical studies and submit a substantially complete 510(k). We have agreed to withdraw the OralStat product from the workplace market if any of the following events occur: 1) we do not submit a substantially complete 510(k) within this specified time period, 2) we fail to submit additional information within time frames specified by FDA, 3) we withdraw our submission, or 4) our 510(k) submission results in FDA&#8217;s determination that the product is not substantially equivalent. On August 3, 2012 the Consent decree was approved and entered by the United States District Court for the Northern District of New York, and on August 3, 2012, we received guidance from FDA. We are currently taking actions that will enable us to submit a 510(k) marketing application to FDA within the time frame specified under the Consent Decree.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In addition, from time to time, the Company is named in legal proceedings in connection with matters that arose during the normal course of business. While the ultimate result of any such litigation cannot be predicted, if we are unsuccessful in defending any such litigation, the resulting financial losses could have an adverse effect on the financial position, results of operations and cash flows of the Company. We are aware of no significant litigation loss contingencies for which management believes it is both probable that a liability has been incurred and that the amount of the loss can be reasonably estimated.</p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Note D &#8211; Line of Credit and Debt</b></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><u>Loan and Security Agreement with Medallion Financial Corp (&#8220;Medallion&#8221;)</u></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On April 20, 2012 (the &#8220;Closing Date&#8221;), we entered into a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with Medallion, a Senior Lender, to refinance the Company&#8217;s Line of Credit with Rosenthal.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Under the Loan Agreement, Medallion is providing the Company with up to $1,000,000 under a revolving secured line of credit (the &#8220;Medallion Line of Credit&#8221;), which is secured by a first security interest in all of the Company&#8217;s receivables, inventory, and intellectual property rights along with a second security interest in the Company&#8217;s machinery and equipment. The maximum amount available under the Medallion Line of Credit is subject to an Advance Rate that consists of: 85% of eligible accounts receivable and up to 30% of eligible inventory (not to exceed $150,000). &#8220;Eligible Receivables&#8221; are defined as those receivables that are paid within ninety (90) days of the invoice date. Eligible Receivables consists of both domestic sales and those international sales made in North America. An Eligible Receivable becomes ineligible if more than 25% of the aggregate receivables due from a customer are more than ninety (90) days past due or the aggregate receivables from a customer exceed 25% of the then total outstanding Eligible Receivables. &#8220;Eligible Inventory&#8221; is defined as raw materials and finished goods that are not obsolete or unmerchantable and are acceptable to Medallion.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">From the loan availability on the Closing Date, we drew approximately $566,000 to pay off our Line of Credit with Rosenthal and Rosenthal, Inc. (&#8220;Rosenthal&#8221;); see below for further information on the Rosenthal Line of Credit).</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We were charged a facility fee of 1% of the balance of the Medallion Line of Credit on the Closing Date and will be charged the same facility fee of 1% on each anniversary of the Closing Date thereafter. Under the Loan Agreement, interest on outstanding borrowings is payable monthly and is charged at an annual rate equal to 4% above a base rate (which is the Wall Street Journal Prime as published from time to time. As of the date of this report, the Wall Street Journal Prime is 3.25%). If we were to default under the Loan Agreement, interest on outstanding borrowings under the Medallion Line of Credit would be charged at an annual rate of 2% above the interest rate in effect at the time of such default. We are subject to two audits per year by Medallion (provided we are not in default) at a rate of $950.00 per person per day. Prior to closing, we also paid a non-refundable fee in the amount of $10,000 to Medallion for field exam and due diligence costs.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">So long as any obligations are due to Medallion under the Medallion Line of Credit, we must maintain stockholders&#8217; equity of at least $1,750,000, and as of the date of this report, we are in compliance with this requirement.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We incurred $20,000 in costs related to the Medallion Line of Credit. These costs were fully expensed in the nine months ended September 30, 2012.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We incurred $8,000 and $31,000 in interest expense in the three and nine months ended September 30, 2012, respectively (no interest expense was incurred in the three and nine months ended September 30, 2011 as we did not close on the Medallion Line of Credit until April 2012).</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The amount outstanding on the Medallion Line of Credit at September 30, 2012 was $565,000. Additional loan availability was $107,000, for a total Loan Availability of $672,000 as of September 30, 2012. No amounts were outstanding or available at September 30, 2011, as we did not close on the Medallion Line of Credit until April 2012.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>&#160;</i></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i><u>Rosenthal Line of Credit</u></i></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We previously entered into a Financing Agreement (the &#8220;Financing Agreement&#8221;) with Rosenthal. On February 28, 2012, we gave Rosenthal written notice of non-renewal as provided under the Financing Agreement, and as a result, the Financing Agreement terminated on May 31, 2012.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Under the Financing Agreement, Rosenthal provided the Company with up to $1,500,000 under a revolving secured line of credit (&#8220;Rosenthal Line of Credit&#8221;). The Rosenthal Line of Credit was collateralized by a first security interest in all of the Company&#8217;s accounts receivables, inventory, and intellectual property, and a second security interest in our machinery and equipment, leases, leasehold improvements, furniture and fixtures. The maximum availability of $1,500,000 was subject to an availability formula based on certain percentages of accounts receivable and inventory, and elements of the availability formula were subject to periodic review and revision by Rosenthal. Under the Financing Agreement, we paid Rosenthal an administrative fee of $1,500 per month and an annual fee of $15,000. There were additional administrative fees paid that totaled $7,000 and $23,000 in the three and nine months ended September 30, 2011, respectively (there were no ($0) additional administrative fees charged in the three and nine months ended September 30, 2012). Under the Financing Agreement, interest was payable monthly, and was charged at variable rates (based on the Prime Rate), with minimum monthly interest of $4,000. We incurred $0 and $19,000, respectively in interest expense in the three and six months ended September 30, 2012. We incurred $14,000 and $42,000, respectively, in interest expense in the three and nine months ended September 30, 2011.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We incurred $41,000 in costs related to the Rosenthal Line of Credit. These costs were amortized over the three-year term of the Rosenthal Line of Credit; with the remaining $4,000 in costs being amortized in the second quarter of 2012. We amortized $0 and $7,000, respectively, in the three and nine months ended September 30, 2012. We amortized $4,000 and $11,000, respectively, in costs in the three and nine months ended September 30, 2011.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In April 2012, we drew approximately $566,000 from our Medallion Line of Credit to pay off the Rosenthal Line of Credit so the amount due on the Rosenthal Line of Credit as of September 30, 2012 was $0. The amount outstanding on the Rosenthal Line of Credit at December 31, 2011 was $397,000, with $361,000 of this amount outstanding collateralized by accounts receivable at an interest rate of 8% and $36,000 collateralized by inventory at an interest rate of 9%. Additional loan availability was $159,000, for a total Loan Availability of $556,000 as of December 31, 2011.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>&#160;</i></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i><u>First Niagara Bank Mortgage Consolidation Loan (&#8220;Mortgage Consolidation Loan&#8221;)</u></i></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On February 23, 2011, we amended and extended our Mortgage Consolidation Loan with First Niagara Bank (&#8220;First Niagara&#8221;). The amended Mortgage Consolidation Loan has a maturity date of March 1, 2013, and has a 6-year (72 month) amortization. The principal amount of the amended Mortgage Consolidation Loan is $815,000 with a fixed interest rate of 8.25%. The monthly payment of principal and interest is $14,000 and payments commenced on March 1, 2011. We were required to make a $15,000 principal payment at the time of closing of the amended Mortgage Consolidation Loan. We also incurred approximately $2,000 in costs associated with this amendment, which were legal costs incurred by First Niagara and passed on to the Company. These costs were fully amortized as of September 30, 2012. The amended Mortgage Consolidation Loan continues to be secured by our facility in Kinderhook, New York as well as various pieces of machinery and equipment. All other terms of the Mortgage Consolidation Loan remain unchanged, including compliance with a covenant (measured monthly) to maintain a certain level of liquidity (defined as any combination of cash, marketable securities or borrowing availability under one or more credit facilities other than the Mortgage Consolidation Loan). As of the date of this report, we are in compliance with this covenant.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The balance on the Mortgage Consolidation Loan was $639,000 at September 30, 2012 and $725,000 at December 31, 2011. Interest expense recognized in the nine months ended September 30, 2012 was $43,000 and interest expense recognized in the nine months ended September 30, 2011 was $50,000. Interest expense was $14,000 and $16,000, respectively, during the three months ended September 30, 2012 and September 30, 2011.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>&#160;</i></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i><u>Copier Leases</u></i></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In May 2007, we purchased a copier through an equipment lease with RICOH in the amount of $17,000. The term of the lease is five years with an interest rate of 14.11%. In April 2012, we notified RICOH that we were opting to purchase the copier for $1.00 as provided in our lease. The amount outstanding on this lease was $0 at September 30, 2012 and $3,000 at December 31, 2011.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In October 2010, we purchased a copier through an equipment lease with Marlin Leasing in the amount of $4,000. The term of the lease is three years with an interest rate of 14.46%. The amount outstanding on this lease was$1,000 at September 30, 2012 and $2,000 at December 31, 2011.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>&#160;</i></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i><u>Debenture Financing</u></i></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In August 2008, we completed an offering of Series A Debentures (&#8220;Series A Debentures&#8221;) and received gross proceeds of $750,000. The net proceeds of the offering of Series A Debentures were $631,000 after $54,000 of placement agent fees and expenses, legal and accounting fees of $63,000 and $2,000 of state filing fees.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Series A Debentures accrued interest at a rate of 10% per annum (payable by the Company semi-annually). As placement agent, Cantone Research, Inc. (&#8220;Cantone&#8221;) received a placement agent fee of $52,500, or 7% of the gross principal amount of Series A Debentures sold. In addition, we issued Cantone a four-year warrant to purchase 30,450 shares of the Company&#8217;s common stock at an exercise price of $0.37 per share (the closing price of the Company&#8217;s common shares on the date of closing) and a four-year warrant to purchase 44,550 shares of the Company&#8217;s common stock at an exercise price of $0.40 per share (the closing price of the Company&#8217;s common stock on the Series A Debentures completion date). All warrants issued to Cantone were immediately exercisable upon issuance. We registered the common shares underlying the Series A Debentures in a registration statement on Form S-3 filed with the SEC on April 15, 2009 and amended on May 5, 2009. On June 10, 2009, the SEC issued a notice of effectiveness related to this Form S-3, as amended.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We incurred $131,000 in expenses related to the offering, including $12,000 in expense related to warrants issued to Cantone. We amortized $19,000 of expense related to these debt issuance costs in the nine months ended September 30, 2012, of which a little under $2,000 was share based payment expense related to the Cantone warrants, and $24,000 of expense in the nine months ended September 30, 2011, of which just over $2,000 was share based payment expense related to the Cantone warrants. We amortized $3,000 of expense in the three months ended September 30, 2012 and $8,000 of expense in the three months ended September 30, 2011; of which less than $1,000 was share based payment expense related to the Cantone warrants in both periods.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The unamortized balance was $0 as of September 30, 2012 (as the Series A Debentures matured on August 1, 2012) and $19,000 as of December 31, 2011. We also had $0 in accrued interest expense related to the Series A Debentures at September 30, 2012 and $31,000 December 31, 2011. The Company recognized $44,000 in interest expense during the nine months ended September 30, 2012 and $56,000 in interest expense during the nine months ended September 30, 2011. The Company recognized $6,000 in interest expense in the three months ended September 30, 2012 and $19,000 in interest expense in the three months ended September 30, 2011.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i><u>Series A Debenture Extension</u></i></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Series A Debentures matured on August 1, 2012. On July 25, 2012, we entered into a Placement Agent Agreement (the &#8220;Agent Agreement&#8221;) with Cantone. Under the terms of the Agent Agreement, Cantone acted as our exclusive placement agent in connection with an amendment of the Series A Debentures. Under the amendment, the term of Series A Debentures was extended to reflect a due date of August 1, 2013, and the interest rate during the extension period was increased from 10% to 15% per annum, due quarterly in arrears.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As compensation for their placement agent services, Cantone received a cash fee of 5% of the gross amount of existing Series A Debentures, or $37,500, and the warrants issued to Cantone (in connection with their services as placement agent in the original Series A Debenture financing) were amended to reflect a purchase price of $0.17 per share and a new term of three (3) years. Cantone also received 1% of the gross amount of Series A Debentures, or $7,500, as a non-accountable expense allowance and we reimbursed Cantone $5,000 in legal fees incurred in connection with the amendment of the Series A Debentures. We will amortize the costs (totaling $50,000) associated with the amendment of the Series A Debentures over the term of the extension (12 months). We amortized $8,000 of these costs in the three months ended September 30, 2012.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On July 30, 2012, we entered into a Bridge Loan Agreement and Note (the &#8220;Bridge Loan&#8221;) with Cantone Asset Management, LLC (&#8220;CAM&#8221;). The Bridge Loan is in the amount of $150,000 and was used to pay $100,000 to those Holders of Series A Debentures that did not wish to amend/extend the Series A Debentures and $50,000 was used to pay placement agent fees and expenses previously indicated in the previous paragraph.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The maturity date of the Bridge Loan is August 1, 2013 and it bears simple interest in advance of 15%. In addition to the interest, on August 1, 2012, the Company instructed its transfer agent to issue CAM restricted stock of the Company equal to 10% of the gross amount of existing Series A Debentures, or $15,000 using a value of $0.17 per common share. On August 8, 2012, 88,235 restricted common shares were issued to CAM.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On July 31, 2012, we entered into an Agreement to the Series A Debenture (the &#8220;Debenture Amendment&#8221;) with thirty-two of the thirty-seven holders of Series A Debentures (the &#8220;Debenture Holders&#8221;) (representing $645,000 of Series A Debentures). As previously indicated, the Debenture Amendment extends the due date of the Series A Debenture to August 31, 2013 and increased the interest rate to 15% per annum, payable quarterly in arrears. All other terms of the Series A Debentures remain unchanged. Five of the Debenture Holders (representing $105,000 in Series A Debentures) did not wish to extend the Series A Debentures and we used proceeds of $100,000 from the Bridge Loan and $5,000 paid directly from the Company to pay principal amounts due to these non-extending Debenture Holders.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On August 1, 2012, the Company entered into a Consulting Agreement (&#8220;Consulting Agreement&#8221;) with CAM. The Consulting Agreement commenced August 1, 2012 and ends on August 1, 2013. Under the terms of the Consulting Agreement, CAM will provide the Company with financial advisory services and advice related to debt refinancing. On August 1, 2012, the Company issued CAM warrants to purchase 300,000 shares of the Company&#8217;s common stock at an exercise price of $0.16 per share (the closing price of the Company&#8217;s common shares on August 1, 2012). The warrants are exercisable through July 31, 2015 and have piggyback registration rights (see Part I, Item 1, Note E, &#8220;Series A Debenture Extension-Warrants&#8221;).</p> <p style="text-align: justify; margin: 0pt 0px; font: bold 10pt times new roman, times, serif;">Note E &#8211; Stock Option Grants / Warrant Grants</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><u>Rosenthal Financing Option Grants</u></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As a condition to the Financing Agreement with Rosenthal, our Chief Executive Officer, Stan Cipkowski (&#8220;Cipkowski&#8221;) was required to execute a Validity Guarantee (the &#8220;Validity Guarantee&#8221;) that includes representations and warranties with respect to the validity of the Company&#8217;s receivables and guarantees the accuracy of the Company&#8217;s reporting to Rosenthal related to its receivables and inventory. The Validity Guarantee places Cipkowski&#8217;s personal assets at risk in the event of a breach of such representations, warranties and guarantees. As part of the compensation for his execution of the Validity Guarantee, on July 1, 2009, Cipkowski was awarded an option grant representing 500,000 common shares of the Company under its Fiscal 2001 Stock Option Plan (the &#8220;2001 Plan&#8221;), at an exercise price of $0.20, the closing price of the Company&#8217;s common shares on the date of the grant. The option grant vests over 3 years in equal installments, and the first 33% (165,000 common shares) of the grant vested on July 1, 2010, the second 33%, (165,000 common shares) vested on July 1, 2011 and the final 34% (170,000 common shares) vested on July 1, 2012. We recognized $78,000 in share-based payment expense amortized over the required service period of 3 years. We recognized $13,000 in share-based payment expense for this grant in the nine months ended September 30, 2012 and $20,000 in share-based payment expense in the nine months ended September 30, 2011. We recognized $0 in share-based payment expense for this grant in the three months ended September 30, 2012 and $6,000 in share-based payment expense in the three months ended September 30, 2011. As of September 30 2012, there was $0 in unrecognized expense with 0 months remaining.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As another condition to the Financing Agreement with Rosenthal, the Company&#8217;s President and Chairman of the Board, Edmund M. Jaskiewicz (&#8220;Jaskiewicz&#8221;) was required to execute an Agreement of Subordination and Assignment (&#8220;Subordination Agreement&#8221;) related to $124,000 owed to Jaskiewicz by the Company as of June 29, 2009 (the &#8220;Jaskiewicz Debt&#8221;). Under the Subordination Agreement, the Jaskiewicz Debt was not payable, was junior in right to the Rosenthal Line of Credit and no payment could be accepted or retained by Jaskiewicz unless and until the Company satisfied in full any obligations to Rosenthal. Furthermore, the Jaskiewicz Debt was assigned and transferred to Rosenthal as collateral for the Rosenthal Line of Credit.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As compensation for his execution of the Subordination Agreement, on July 1, 2009 Jaskiewicz was awarded an option grant representing 50,000 common shares of the Company under its 2001 Plan at an exercise price of $0.20, the closing price of the Company&#8217;s common shares on July 1, 2009. The option grant (50,000 common shares) was 100% immediately exercisable on July 31, 2009. We recognized $8,000 during the year ended December 31, 2009 in share-based payment expense related to the grant of Jaskiewicz&#8217;s options upon issuance of the grant.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On July 1, 2010 (the first anniversary of the original stock option grant date of July 1, 2009), Jaskiewicz was awarded a second option grant representing 50,000 common shares of the Company under the Company&#8217;s 2001 Plan, at an exercise price of $0.07, the closing price of the Company&#8217;s common shares on July 1, 2010. The option grant (50,000 common shares) was 100% immediately exercisable on July 1, 2010. During the year ended December 31, 2010, we recognized $3,000 in share-based payment expense for this grant.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On July 1, 2011, (the second anniversary of the original stock option grant date of July 1, 2009), Jaskiewicz was awarded an additional option grant representing 50,000 common shares of the Company under the Company&#8217;s 2001 Plan, at an exercise price of $0.12, the closing price of the Company&#8217;s common shares on July 1, 2011. The option grant (50,000 common shares) was 100% immediately exercisable on July 1, 2011. We recognized the full share-based payment expense of $6,000 in the three months ended September 30, 2011.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><u>December 2010 Employee Grant</u></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On December 31, 2010, we issued options to purchase 275,000 shares of common stock under the 2001 Plan to 4 members of senior management and 8 other employees of the Company at an exercise price of $0.09 (the closing price of the Company&#8217;s common shares on December 31, 2010). These option grants vested 100% (275,000 common shares) on December 31, 2011. We recognized $25,000 in share-based payment expense over the required service period of one year. We recognized $0 in share-based payment expense related to these grants in the nine months ended September 30, 2012, and $20,000 of this expense in the nine months ended September 30, 2011. As of September 30, 2012, there was $0 in unrecognized expenses with 0 months remaining.</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><u>Medallion Line of Credit Stock Options</u></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As a condition to the Medallion Line of Credit, Cipkowski and our controller J. Duncan Urquhart (&#8220;Urquhart&#8221;) were each required to execute Validity Guarantees (the &#8220;Validity Guarantees&#8221;). Under the Validity Guarantees, Cipkowski and Urquhart provide representations and warranties with respect to the validity of our receivables as well as guaranteeing the accuracy of our reporting to Medallion related to the Company&#8217;s receivables.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>&#160;</i></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>Cipkowski Medallion Grant</i></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As compensation for his execution of the Validity Guarantee, on April 20, 2012, Cipkowski was awarded an option grant representing 250,000 common shares of the Company under the Company&#8217;s Fiscal 2001 stock option plan, at an exercise price of $0.18, the closing price of our common shares on April 20, 2012. The option grants vest over three (3) years in installments of 33% on April 20, 2013 (82,500 common shares), 33% on April 20, 2014 (82,500 common shares) and 34% (85,000 common shares) on April 20, 2015.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The fair value of the Cipkowski stock option grants was estimated utilizing the Black-Scholes option-pricing model. The following weighted average assumptions were used: dividend yield of 0%; risk-free interest rate of 1.99; expected life of 10 years; and stock price volatility of 88%. The value of the stock option grant is $45,000 and the Company will recognize this share-based payment expense over the vesting period of 3 years. We recognized $4,000 in share-based payment expense in the three months ended September 30, 2012 and $8,000 in the nine months ended September 30, 2012. As of September 30, 2012, there was $37,000 in unrecognized share-based payment expense with 30 months remaining.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>&#160;</i></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>Urquhart Medallion Grant</i></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As compensation for his execution of the Validity Guarantee, on April 20, 2012, Urquhart was awarded an option grant representing 250,000 common shares of the Company under the Company&#8217;s Fiscal 2001 stock option plan, at an exercise price of $0.18, the closing price of our common shares on April 20, 2012. The option grants vest over three (3) years in installments of 33% (82,500 common shares) on April 20, 2013, 33% (82,500 common shares) on April 20, 2014 and 34% (85,000 common shares) on April 20, 2015.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The fair value of the Urquhart stock option grant was estimated utilizing the Black-Scholes option-pricing model. The following weighted average assumptions were used: dividend yield of 0%; risk-free interest rate of 1.99; expected life of 10 years; and stock price volatility of 88%. The value of the stock option grant is $45,000 and the Company will recognize this share-based payment expense over the vesting period of 3 years. We recognized $4,000 in share-based payment expense in the three months ended September 30, 2012 and $8,000 in the nine months ended September 30, 2012. As of September 30, 2012, there was $37,000 in unrecognized share-based payment expense with 30 months remaining.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>&#160;</i></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>Jaskiewicz Medallion Grant</i></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As another condition to the Medallion Line of Credit, Jaskiewicz was required to execute another Subordination Agreement (&#8220;Subordination Agreement&#8221;) related to the Jaskiewicz Debt (the $124,000 currently owed to Jaskiewicz by the Company). Under the Subordination Agreement, the Jaskiewicz Debt is not payable, is junior in right to the Medallion Line of Credit and no payment may be accepted or retained by Jaskiewicz for the Jaskiewicz Debt unless and until we have paid and satisfied in full any obligations to Medallion. As compensation for his execution of the Subordination Agreement, on April 20, 2012 Jaskiewicz was awarded an option grant representing 150,000 common shares of the Company under the Company&#8217;s Fiscal 2001 stock option plan, at an exercise price of $0.18, the closing price of the Company&#8217;s common shares on April 20, 2012. The option grant vests over three (3) years in installments as follows: 33% (49,500 common shares) on April 20, 2013, 33% (49,500 common shares) on April 20, 2014 and 34% (51,000 common shares) on April 20, 2015.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The fair value of the Jaskiewicz stock option grant was estimated utilizing the Black-Scholes option-pricing model. The following weighted average assumptions were used: dividend yield of 0%; risk-free interest rate of 1.99; expected life of 10 years; and stock price volatility of 88%. The value of the stock option grant is $27,000 and the Company will recognize this share-based payment expense over the vesting period of 3 years. We recognized $2,000 in share-based payment expense in the three months ended September 30, 2012 and $4,000 in share-based payment expense in the nine months ended September 30, 2012. As of September 30, 2012, there was $23,000 in unrecognized share-based payment expense with 30 months remaining.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;<i>&#160;</i></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>CRI Warrants</i></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On July 31, 2012, we issued CRI warrants to purchase 75,000 shares of the Company&#8217;s common stock at an exercise price of $0.17 per share (the closing price of the Company&#8217;s common shares on July 31, 2012) (&#8220;CRI Warrants&#8221;). The CRI warrants are exercisable through July 31, 2015 (see Part I, Item I, Note E, &#8220;Series A Debenture Extension&#8221;). The fair value of the CRI Warrants was estimated utilizing the Black-Scholes option-pricing model. The following weighted average assumptions were used: dividend yield of 0%; risk-free interest rate of 1.51; expected life of 3 years; and stock price volatility of 77%. The value of the CAM Warrant is $12,000 and the Company recognized $12,000 (or the full expense) in share based payment expense in the three and nine months ended September 30, 2012.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>CAM Warrants</i></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On August 1, 2012, we issued CAM warrants to purchase 300,000 shares of the Company&#8217;s common stock at an exercise price of $0.16 per share (the closing price of the Company&#8217;s common shares on August 1, 2012) (&#8220;CAM Warrants&#8221;). The CAM Warrants are exercisable through July 31, 2015 and have piggyback registration rights (see Part I, Item I, Note E, &#8220;Series A Debenture Extension&#8221;). The fair value of the CAM Warrants was estimated utilizing the Black-Scholes option-pricing model. The following weighted average assumptions were used: dividend yield of 0%; risk-free interest rate of 1.56; expected life of 3 years; and stock price volatility of 77%. The value of the CAM Warrant is $48,000 and the Company recognized $48,000 (or the full expense) in share based payment expense in the three and nine months ended September 30, 2012.</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><u>September 2012 Employee Grants</u></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="font: 10pt times new roman, times, serif;">On September 20, 2012, we issued 2 stock option grants to purchase 50,000 shares (for a total of 100,000) of the Company&#8217;s common stock to 2 non-executive employees at an exercise price of $0.18 (the closing price of the Company&#8217;s common shares on September 20, 2012). Both option grants vest over 3 years in installments as follows: 33% (33,000 common shares total) on September 20, 2013, 33% (33,000 common shares total) on September 20, 2014 and 34% (34,000 common shares total) on September 20, 2015.</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We will recognize $18,000 in share-based payment expense over the vesting period of 3 years. We recognized less than $1,000 in share-based payment expense related to these grants in the three and nine months ended September 30, 2012. As of September 30, 2012, there was over $17,000 in unrecognized expenses with 35 months remaining.</p> <div>Potential common shares outstanding as of September 30, 2012 and 2011: <div style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;</div> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p> <table align="center" style="width: 70%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">September 30, 2012</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">September 30, 2011</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="width: 32%; font-weight: bold;">Warrants</td> <td style="width: 1%; font-weight: bold;">&#160;</td> <td style="width: 1%;">&#160;</td> <td style="width: 1%;">&#160;</td> <td style="text-align: right; width: 31%;">375,000</td> <td style="width: 1%;">&#160;</td> <td style="width: 1%;">&#160;</td> <td style="width: 1%;">&#160;</td> <td style="text-align: right; width: 30%;">75,000</td> <td style="width: 1%;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="font-weight: bold;">Options</td> <td style="font-weight: bold;">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;">3,139,080</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;">3,081,580</td> <td></td> </tr> </table> <div style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</div> &#160;</div> 75000 375000 3081580 3139080 9000000 1000000 150000 9 Medallion 1500000 1000000 672000 0.85 0.30 397000 566000 565000 10000 1,750,000 31000 4000 0 41000 20000 19000 16000 14000 56000 50000 42000 6000 14000 0 8000 44000 43000 19000 31000 159000 150000 107000 1500 15000 7000 23000 0 0 0 4000 4000 4000 19000 361000 0.08 36000 0.09 556000 2013-03-01 P6Y 815000 0.0825 14000 15000 2000 725000 639000 17000 4000 5 Years 3 Years 0.1411 0.1446 3000 2000 0 1000 $1.00 750000 631000 54000 52500 63000 2000 0.10 0.07 44550 30450 0.4 0.16 0.37 $131,000 $12,000 2009-04-15 2009-05-05 8000 4000 24000 11000 3000 0 19000 7000 1000 2000 20000 19000 25000 1000 2000 Charged the same facility fee of 1% on each anniversary Two audits per year by Medallion (provided we are not in default) at a rate of $950.00 per person per day Annual rate equal to 4% above a base rate An annual rate of 2% above the interest rate 0.25 0.0325 0.10 0.15 0.05 37500 0.17 P3Y 0.01 7500 950 5000 P12M 150000 100000 50000 2013-08-01 2013-08-01 0.15 0.10 15000 0.17 88235 645000 0.15 105000 5000 100000 300000 0.33 0.33 1.00 0.34 0.33 0.33 0.34 0.33 0.33 0.34 0.33 0.33 0.34 165000 165000 170000 82500 82500 85000 82500 82500 85000 49500 49500 51000 33000 33000 34000 P3Y P3Y 50000 500000 50000 275000 275000 50000 1.00 1.00 1.00 P10M P9M P2Y11M P2Y6M P2Y6M P2Y6M P0Y 2 250000 150000 250000 45000 27000 45000 0.00 0.00 0.00 0.00 0.00 0.0156 0.0151 0.0199 0.0199 0.0199 P3Y P3Y P10Y P10Y P10Y 0.77 0.77 0.88 0.88 0.88 P3Y P3Y P3Y P3Y 300000 75000 0.16 0.17 48000 12000 P1Y P1Y 50000 100000 0.20 0.20 0.07 0.09 0.09 0.12 P3Y P3Y P3Y 124000 78000 7000 40000 9000 17000 37000 23000 37000 0 124000 0.18 0.18 0.18 0.18 18000 2000 0.00 0.0199 P10Y 0.88 27000 23000 0 14000 0 0 00008967472012-07-30 0000896747abmc:ThirtySevenDebenturesHoldersMember2012-07-31 0000896747abmc:FiveDebenturesHoldersMember2012-07-31